2 Reasons to Like BMRN (and 1 Not So Much)

BioMarin Pharmaceutical currently trades at $61.02 per share and has shown little upside over the past six months, posting a middling return of 3.5%.

Does this present a buying opportunity for BMRN? Or is its underperformance reflective of its story and business quality? Find out in our full research report, it’s free.

Why Does BioMarin Pharmaceutical Spark Debate?

Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.

Two Things to Like:

1. Long-Term Revenue Growth Shows Momentum

A company’s long-term sales performance is one signal of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Thankfully, BioMarin Pharmaceutical’s 11.6% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

2. Increasing Free Cash Flow Margin Juices Financials

If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.

As you can see below, BioMarin Pharmaceutical’s margin expanded by 17.2 percentage points over the last five years. This is encouraging, and we can see it became a less capital-intensive business because its free cash flow profitability rose more than its operating profitability. BioMarin Pharmaceutical’s free cash flow margin for the trailing 12 months was 22.5%.

One Reason to be Careful:

Previous Growth Initiatives Haven’t Impressed

Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity).

Although BioMarin Pharmaceutical has shown solid fundamentals lately, it historically did a mediocre job investing in profitable growth initiatives. Its five-year average ROIC was 2.4%, lower than the typical cost of capital (how much it costs to raise money) for healthcare companies.

Final Judgment

BioMarin Pharmaceutical has huge potential even though it has some open questions, but at $61.02 per share (or 11.7× forward P/E), is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.

Stocks We Like Even More Than BioMarin Pharmaceutical

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.